Recent Publications on : |  |
Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells.
Context: The V600E mutation accounts for the vast majority of thyroid...
Direct Link | 3rd November, 2009
| Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto
|
Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas.
PURPOSE: Thymomas and thymic carcinomas are rare intrathoracic...
Direct Link | 29th October, 2009
| Authors' Affiliations: Human Oncology and Pathogenesis Program (HOPP);
|
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.
Genes mutated in congenital malformation syndromes are frequently...
Direct Link | 27th October, 2009
|
|
Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers.
Summary Background Actinic keratosis (AK) is a well-established...
Direct Link | 24th October, 2009
| Laboratory of Clinical Virology, Medical School, University of Crete,
|
RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact.
Context: Poorly differentiated carcinomas represent an aggressive group of...
Direct Link | 20th October, 2009
| Department of Clinical and Biological Sciences (M.V., I.R., D.G., M.P.),
|
| Factors associated with incidental sickness absence among employees in one health care system.
| 9th October, 2009
| Health Management Research Center, University of Michigan, 1015 East Huron
|
Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation.
Recent findings have shown that malignant tumors contain cancer-initiating...
Direct Link | 8th October, 2009
| Laboratory for Cell Lineage Modulation, RIKEN Center for Developmental
|
Predicting Recurrence and Progression of Noninvasive Papillary Bladder Cancer at Initial Presentation Based on Quantitative Gene Expression Profiles.
BACKGROUND: Currently, tumor grade is the best predictor of outcome at...
Direct Link | 19th September, 2009
| Department of Urology, University of Southern California Keck School of
|
Health risk appraisals: how much do they influence employees' health behavior?
Health plans often use health risk appraisals (HRAs) as a starting point...
Direct Link | 10th September, 2009
| Harvard Medical School, Boston, Massachusetts, USA.
|
NAG7 promotes human nasopharyngeal carcinoma invasion through inhibition of estrogen receptor alpha and up-regulation of JNK2/AP-1/MMP1 pathways.
The NAG7, an estrogen receptor repressor, is a negative regulator of...
Direct Link | 10th September, 2009
| Cancer Research Institute, Central South University, Changsha, Hunan, PR
|
RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.
Rhabdomyosarcoma (RMS) is a common childhood solid tumor, resulting from...
Direct Link | 15th August, 2009
| Department of Hematology, Oncology and Molecular Medicine, Istituto
|
Recurring G12S Mutation of HRAS in a Chinese Child with Costello Syndrome with High Alkaline Phosphatase Level.
Rhabdomyosarcoma (RMS) is a common childhood solid tumor, resulting from...
Direct Link | 12th August, 2009
| Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua
|
Health risk reduction programs in employer-sponsored health plans: Part I-efficacy.
OBJECTIVE: We sought to determine whether workplace health risk reduction...
Direct Link | 25th July, 2009
| Institute for Bioethics, Health Policy and Law, University of Louisville
|
Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes.
Tazarotene-induced protein 3 (TIG3) and HRAS-like suppressor family 2...
Direct Link | 21st July, 2009
| Department of Biochemistry, Kagawa University School of Medicine, 1750-1
|
microRNA expression during trophectoderm specification.
BACKGROUND: Segregation of the trophectoderm from the inner cell mass of...
Direct Link | 8th July, 2009
| Department of Biological Chemistry and Molecular Pharmacology, Harvard
|
